| Source | Evidence on protein | Close homologs |
|---|---|---|
| Cuervo et al. | no | yes: 0 |
| Hassani et al. | no | yes: 0 |
| Forrest at al. (metacyclic) | no | yes: 0 |
| Forrest at al. (procyclic) | no | yes: 0 |
| Silverman et al. | no | yes: 0 |
| Pissara et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Pires et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Silverman et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Jamdhade et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| DeepLoc | ||
| SignalP6 | no | yes: 0, no: 10 |
| NetGPI | no | yes: 0, no: 10 |
| Term | Name | Level | Count |
|---|---|---|---|
| GO:0005730 | nucleolus | 5 | 1 |
| GO:0043226 | organelle | 2 | 1 |
| GO:0043228 | non-membrane-bounded organelle | 3 | 1 |
| GO:0043229 | intracellular organelle | 3 | 1 |
| GO:0043232 | intracellular non-membrane-bounded organelle | 4 | 1 |
| GO:0110165 | cellular anatomical entity | 1 | 1 |
Related structures:
AlphaFold database: A0A3S7WUY3
| Leishmania | From | To | Domain/Motif | Score |
|---|---|---|---|---|
| CLV_C14_Caspase3-7 | 168 | 172 | PF00656 | 0.735 |
| CLV_C14_Caspase3-7 | 24 | 28 | PF00656 | 0.743 |
| CLV_NRD_NRD_1 | 102 | 104 | PF00675 | 0.527 |
| CLV_NRD_NRD_1 | 111 | 113 | PF00675 | 0.464 |
| CLV_NRD_NRD_1 | 13 | 15 | PF00675 | 0.603 |
| CLV_NRD_NRD_1 | 4 | 6 | PF00675 | 0.600 |
| CLV_NRD_NRD_1 | 96 | 98 | PF00675 | 0.469 |
| CLV_PCSK_FUR_1 | 100 | 104 | PF00082 | 0.635 |
| CLV_PCSK_KEX2_1 | 102 | 104 | PF00082 | 0.552 |
| CLV_PCSK_KEX2_1 | 111 | 113 | PF00082 | 0.516 |
| CLV_PCSK_KEX2_1 | 141 | 143 | PF00082 | 0.588 |
| CLV_PCSK_KEX2_1 | 4 | 6 | PF00082 | 0.601 |
| CLV_PCSK_PC1ET2_1 | 141 | 143 | PF00082 | 0.588 |
| CLV_PCSK_SKI1_1 | 119 | 123 | PF00082 | 0.509 |
| CLV_PCSK_SKI1_1 | 16 | 20 | PF00082 | 0.609 |
| CLV_PCSK_SKI1_1 | 5 | 9 | PF00082 | 0.717 |
| CLV_PCSK_SKI1_1 | 75 | 79 | PF00082 | 0.473 |
| CLV_PCSK_SKI1_1 | 84 | 88 | PF00082 | 0.423 |
| DOC_USP7_MATH_1 | 21 | 25 | PF00917 | 0.768 |
| DOC_USP7_UBL2_3 | 15 | 19 | PF12436 | 0.635 |
| DOC_USP7_UBL2_3 | 37 | 41 | PF12436 | 0.691 |
| DOC_USP7_UBL2_3 | 71 | 75 | PF12436 | 0.603 |
| LIG_LIR_Gen_1 | 163 | 172 | PF02991 | 0.660 |
| LIG_LIR_Nem_3 | 163 | 169 | PF02991 | 0.659 |
| LIG_SH2_STAT3 | 117 | 120 | PF00017 | 0.455 |
| LIG_SH2_STAT5 | 117 | 120 | PF00017 | 0.455 |
| MOD_CK1_1 | 131 | 137 | PF00069 | 0.591 |
| MOD_CK2_1 | 131 | 137 | PF00069 | 0.529 |
| MOD_GlcNHglycan | 24 | 27 | PF01048 | 0.692 |
| MOD_GSK3_1 | 128 | 135 | PF00069 | 0.448 |
| MOD_GSK3_1 | 17 | 24 | PF00069 | 0.647 |
| MOD_PKA_1 | 22 | 28 | PF00069 | 0.669 |
| MOD_Plk_1 | 131 | 137 | PF00069 | 0.601 |
| MOD_Plk_2-3 | 132 | 138 | PF00069 | 0.489 |
| MOD_SUMO_for_1 | 107 | 110 | PF00179 | 0.470 |
| MOD_SUMO_for_1 | 121 | 124 | PF00179 | 0.529 |
| MOD_SUMO_rev_2 | 134 | 143 | PF00179 | 0.586 |
| TRG_DiLeu_BaEn_1 | 139 | 144 | PF01217 | 0.552 |
| TRG_DiLeu_LyEn_5 | 139 | 144 | PF01217 | 0.581 |
| TRG_ER_diArg_1 | 100 | 103 | PF00400 | 0.524 |
| TRG_ER_diArg_1 | 4 | 6 | PF00400 | 0.600 |
| TRG_ER_diArg_1 | 48 | 51 | PF00400 | 0.726 |
| TRG_NLS_Bipartite_1 | 4 | 20 | PF00514 | 0.612 |
| TRG_NLS_Bipartite_1 | 57 | 74 | PF00514 | 0.607 |
| TRG_NLS_MonoCore_2 | 13 | 18 | PF00514 | 0.631 |
| TRG_NLS_MonoExtC_3 | 14 | 19 | PF00514 | 0.616 |
| TRG_NLS_MonoExtN_4 | 11 | 18 | PF00514 | 0.614 |
| TRG_Pf-PMV_PEXEL_1 | 119 | 123 | PF00026 | 0.481 |
| TRG_Pf-PMV_PEXEL_1 | 142 | 146 | PF00026 | 0.570 |
| Protein | Taxonomy | Sequence identity | Coverage |
|---|---|---|---|
| A0A0N1I9L1 | Leptomonas seymouri | 69% | 98% |
| A0A0S4JFM3 | Bodo saltans | 41% | 100% |
| A0A1X0P6Y6 | Trypanosomatidae | 45% | 100% |
| A4H9K6 | Leishmania braziliensis | 85% | 100% |
| A4HXX1 | Leishmania infantum | 100% | 100% |
| C9ZZT1 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 44% | 100% |
| E9ARN5 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 90% | 100% |
| Q4QDU4 | Leishmania major | 93% | 99% |
| V5B6M9 | Trypanosoma cruzi | 44% | 100% |